<p>Rani Therapeutics（納斯達克代碼：RANI - 獲取免費報告）於週四發佈了季度財報。該公司報告每股收益（EPS）為（$0.12），低於分析師一致預期的（$0.09），差距為（$0.03），FiscalAI 報道。</p>
<p>獲取 <strong>Rani Therapeutics</strong> 的提醒：</p>
<h2>Rani Therapeutics 股票表現</h2>
<p>納斯達克 RANI 週五下跌 $0.25，報 $2.02。該股票的交易量為 6,407,335 股，而其平均交易量為 53,376,040 股。Rani Therapeutics 的 12 個月低點為 $0.39，12 個月高點為 $3.87。該公司的 50 日移動平均價格為 $1.00，200 日移動平均價格為 $0.75。該股票的市值為 $145.18 百萬，市盈率為 -2.56，貝塔值為 0.38。</p>
<h2>內部活動</h2>
<p>在其他 Rani Therapeutics 的新聞中，主要股東 South Cone Investments Limited 於 10 月 21 日（星期二）出售了 4,000,000 股 Rani Therapeutics 股票。該股票以平均價格 $2.77 出售，總交易額為 $11,080,000.00。交易完成後，內部人士持有該公司 2,379,194 股，估值約為 $6,590,367.38。此次交易使其持股減少了 62.70%。該出售在與 SEC 的法律文件中披露，您可以通過此鏈接訪問。此外，董事 Mir A. Imran 於 10 月 23 日（星期四）購買了 2,083,334 股該股票。該股票以每股平均成本 $0.60 購買，總價值為 $1,250,000.40。交易完成後，該董事直接持有該公司 2,083,334 股，估值為 $1,250,000.40。此次交易代表其持股的 ∞ 增加。該購買的披露在 SEC 文件中可用。公司內部人士持有 45.08% 的股票。</p>
<h2>機構資金流入和流出</h2>
<p>一家對沖基金最近在 Rani Therapeutics 股票中購買了新股份。Armistice Capital LLC 在第二季度購買了 Rani Therapeutics Holdings, Inc.（納斯達克代碼：RANI - 免費報告）的新頭寸，根據其最近向證券交易委員會的文件。該基金購買了 3,151,354 股該公司的股票，估值約為 $1,619,000。Armistice Capital LLC 在最近的報告期末持有 Rani Therapeutics 約 4.99% 的股份。對沖基金和其他機構投資者持有該公司 30.19% 的股票。</p>
<h2>華爾街分析師預測增長</h2>
<p>多家券商對 RANI 發表了評論。Maxim Group 將 Rani Therapeutics 的股票目標價從 $5.00 上調至 $10.00，並在 10 月 20 日（星期一）的研究報告中給予該股票 &#34;買入&#34; 評級。HC Wainwright 在 10 月 21 日（星期二）的研究報告中重申了 &#34;買入&#34; 評級，並設定了 $11.00 的目標價。Wall Street Zen 在 8 月 16 日（星期六）的報告中將 Rani Therapeutics 的股票評級從 &#34;賣出&#34; 上調至 &#34;持有&#34;。最後，Weiss Ratings 在 10 月 31 日（星期五）的研究報告中重申了 Rani Therapeutics 的 &#34;賣出（d-）&#34; 評級。四位研究分析師對該股票給予了買入評級，一位則對該公司發佈了賣出評級。根據 MarketBeat.com 的數據，該公司目前的平均評級為 &#34;適度買入&#34;，平均目標價為 $8.50。</p>
<p><strong>閲讀我們關於 Rani Therapeutics 的最新股票報告</strong></p>
<h2>Rani Therapeutics 公司簡介</h2>
<p>（獲取免費報告）</p>
<p>Rani Therapeutics Holdings, Inc. 作為一家臨牀階段的生物治療公司，開發用於美國患者、醫生和醫療系統的口服生物製劑。該公司開發了 RaniPill 膠囊，這是一種藥物無關的口服遞送平台，用於遞送多種藥物成分，包括寡核苷酸、肽、蛋白質和抗體。</p>
<h2>進一步閲讀</h2>
<ul>
<li>我們更看好的五隻股票，而不是 Rani Therapeutics</li>
<li>最佳 ESG 股票：11 只最佳 ESG 投資股票</li>
<li>OpenAI 的重組為可能成為有史以來最大 IPO 的機會鋪平了道路</li>
<li>如何做空納斯達克：易於遵循的指南</li>
<li>美國政府不希望失敗的 2 只稀土股票</li>
<li>寵物是大生意：4 只大票寵物股票可加入您的投資組合</li>
<li>CrowdStrike 與 CoreWeave 合作，但投資者拋售消息</li>
</ul>
<p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/EarningsChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9UkFOSQ?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/EarningsChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9UkFOSQ"/></p>
<p><em>此即時新聞提醒由敍述科學技術和來自 MarketBeat 的金融數據生成，以便為讀者提供最快的報道和公正的覆蓋。請將任何問題或意見發送至 contact@marketbeat.com。</em></p>
<h2>你現在應該投資 $1,000 在 Rani Therapeutics 嗎？</h2>
<p>在考慮 Rani Therapeutics 之前，您需要聽聽這個。</p>
<p>MarketBeat 每天跟蹤華爾街頂級評級和表現最佳的研究分析師及其推薦的股票。MarketBeat 已識別出五隻頂級分析師正在悄悄向客户推薦的股票，以便在更廣泛的市場注意到之前購買... 而 Rani Therapeutics 並不在名單上。</p>
<p>雖然 Rani Therapeutics 目前在分析師中獲得了適度買入評級，但頂級分析師認為這五隻股票更值得購買。</p>
<p>在這裏查看這五隻股票</p>

RANI

<p>Rani Therapeutics（納斯達克代碼：RANI）報告的季度收益為每股虧損 0.12 美元，低於預期的每股虧損 0.09 美元，差距為 0.03 美元。股價下跌至 2.02 美元，市值為 1.4518 億美元。主要股東南美投資公司出售了 400 萬股，而董事 Mir A. Imran 購買了 208 萬股。機構持股比例為 30.19%。分析師的評級不一，目標價格範圍在 5.00 美元到 11.00 美元之間，反映出 “適度買入” 的平均評級</p>

<p>Rani Therapeutics (NASDAQ:RANI - Get Free Report) issued its quarterly earnings data on Thursday. The company reported ($0.12) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.09) by ($0.03), FiscalAI reports.</p>
<div class="lb-trans"><p>Rani Therapeutics（納斯達克代碼：RANI - 獲取免費報告）於週四發佈了季度財報。該公司報告每股收益（EPS）為（$0.12），低於分析師一致預期的（$0.09），差距為（$0.03），FiscalAI 報道。</p>
</div><p>Get <strong>Rani Therapeutics</strong> alerts:</p>
<div class="lb-trans"><p>獲取 <strong>Rani Therapeutics</strong> 的提醒：</p>
</div><h2>Rani Therapeutics Stock Performance</h2>
<div class="lb-trans"><h2>Rani Therapeutics 股票表現</h2>
</div><p>NASDAQ RANI traded down $0.25 on Friday, reaching $2.02. The stock had a trading volume of 6,407,335 shares, compared to its average volume of 53,376,040. Rani Therapeutics has a 12-month low of $0.39 and a 12-month high of $3.87. The business's 50-day moving average price is $1.00 and its 200 day moving average price is $0.75. The stock has a market cap of $145.18 million, a P/E ratio of -2.56 and a beta of 0.38.</p>
<div class="lb-trans"><p>納斯達克 RANI 週五下跌 $0.25，報 $2.02。該股票的交易量為 6,407,335 股，而其平均交易量為 53,376,040 股。Rani Therapeutics 的 12 個月低點為 $0.39，12 個月高點為 $3.87。該公司的 50 日移動平均價格為 $1.00，200 日移動平均價格為 $0.75。該股票的市值為 $145.18 百萬，市盈率為 -2.56，貝塔值為 0.38。</p>
</div><h2>Insider Activity</h2>
<div class="lb-trans"><h2>內部活動</h2>
</div><p>In other Rani Therapeutics news, major shareholder South Cone Investments Limited sold 4,000,000 shares of Rani Therapeutics stock in a transaction dated Tuesday, October 21st. The shares were sold at an average price of $2.77, for a total transaction of $11,080,000.00. Following the completion of the transaction, the insider owned 2,379,194 shares in the company, valued at approximately $6,590,367.38. The trade was a 62.70% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is accessible through this link. Also, Director Mir A. Imran bought 2,083,334 shares of the stock in a transaction on Thursday, October 23rd. The stock was purchased at an average cost of $0.60 per share, with a total value of $1,250,000.40. Following the completion of the purchase, the director directly owned 2,083,334 shares in the company, valued at $1,250,000.40. This trade represents a ∞ increase in their position. The disclosure for this purchase is available in the SEC filing. 45.08% of the stock is owned by company insiders.</p>
<div class="lb-trans"><p>在其他 Rani Therapeutics 的新聞中，主要股東 South Cone Investments Limited 於 10 月 21 日（星期二）出售了 4,000,000 股 Rani Therapeutics 股票。該股票以平均價格 $2.77 出售，總交易額為 $11,080,000.00。交易完成後，內部人士持有該公司 2,379,194 股，估值約為 $6,590,367.38。此次交易使其持股減少了 62.70%。該出售在與 SEC 的法律文件中披露，您可以通過此鏈接訪問。此外，董事 Mir A. Imran 於 10 月 23 日（星期四）購買了 2,083,334 股該股票。該股票以每股平均成本 $0.60 購買，總價值為 $1,250,000.40。交易完成後，該董事直接持有該公司 2,083,334 股，估值為 $1,250,000.40。此次交易代表其持股的 ∞ 增加。該購買的披露在 SEC 文件中可用。公司內部人士持有 45.08% 的股票。</p>
</div><h2>Institutional Inflows and Outflows</h2>
<div class="lb-trans"><h2>機構資金流入和流出</h2>
</div><p>A hedge fund recently bought a new stake in Rani Therapeutics stock. Armistice Capital LLC bought a new position in Rani Therapeutics Holdings, Inc. (NASDAQ:RANI - Free Report) during the second quarter, according to its most recent filing with the Securities and Exchange Commission. The fund bought 3,151,354 shares of the company's stock, valued at approximately $1,619,000. Armistice Capital LLC owned approximately 4.99% of Rani Therapeutics at the end of the most recent reporting period. Hedge funds and other institutional investors own 30.19% of the company's stock.</p>
<div class="lb-trans"><p>一家對沖基金最近在 Rani Therapeutics 股票中購買了新股份。Armistice Capital LLC 在第二季度購買了 Rani Therapeutics Holdings, Inc.（納斯達克代碼：RANI - 免費報告）的新頭寸，根據其最近向證券交易委員會的文件。該基金購買了 3,151,354 股該公司的股票，估值約為 $1,619,000。Armistice Capital LLC 在最近的報告期末持有 Rani Therapeutics 約 4.99% 的股份。對沖基金和其他機構投資者持有該公司 30.19% 的股票。</p>
</div><h2>Wall Street Analysts Forecast Growth</h2>
<div class="lb-trans"><h2>華爾街分析師預測增長</h2>
</div><p>A number of brokerages have commented on RANI. Maxim Group lifted their price objective on shares of Rani Therapeutics from $5.00 to $10.00 and gave the stock a &#34;buy&#34; rating in a research note on Monday, October 20th. HC Wainwright reissued a &#34;buy&#34; rating and set a $11.00 price target on shares of Rani Therapeutics in a research report on Tuesday, October 21st. Wall Street Zen raised shares of Rani Therapeutics from a &#34;sell&#34; rating to a &#34;hold&#34; rating in a report on Saturday, August 16th. Finally, Weiss Ratings reaffirmed a &#34;sell (d-)&#34; rating on shares of Rani Therapeutics in a research report on Friday, October 31st. Four research analysts have rated the stock with a Buy rating and one has issued a Sell rating to the company. According to data from MarketBeat.com, the company currently has an average rating of &#34;Moderate Buy&#34; and an average target price of $8.50.</p>
<div class="lb-trans"><p>多家券商對 RANI 發表了評論。Maxim Group 將 Rani Therapeutics 的股票目標價從 $5.00 上調至 $10.00，並在 10 月 20 日（星期一）的研究報告中給予該股票 &#34;買入&#34; 評級。HC Wainwright 在 10 月 21 日（星期二）的研究報告中重申了 &#34;買入&#34; 評級，並設定了 $11.00 的目標價。Wall Street Zen 在 8 月 16 日（星期六）的報告中將 Rani Therapeutics 的股票評級從 &#34;賣出&#34; 上調至 &#34;持有&#34;。最後，Weiss Ratings 在 10 月 31 日（星期五）的研究報告中重申了 Rani Therapeutics 的 &#34;賣出（d-）&#34; 評級。四位研究分析師對該股票給予了買入評級，一位則對該公司發佈了賣出評級。根據 MarketBeat.com 的數據，該公司目前的平均評級為 &#34;適度買入&#34;，平均目標價為 $8.50。</p>
</div><p><strong>Read Our Latest Stock Report on Rani Therapeutics</strong></p>
<div class="lb-trans"><p><strong>閲讀我們關於 Rani Therapeutics 的最新股票報告</strong></p>
</div><h2>Rani Therapeutics Company Profile</h2>
<div class="lb-trans"><h2>Rani Therapeutics 公司簡介</h2>
</div><p>(Get Free Report)</p>
<div class="lb-trans"><p>（獲取免費報告）</p>
</div><p>Rani Therapeutics Holdings, Inc operates as a clinical stage biotherapeutics company that develops orally administered biologics for patients, physicians, and healthcare systems in the United States. The company develops the RaniPill capsule, a drug-agnostic oral delivery platform to deliver a variety of drug substances, including oligonucleotides, peptides, proteins, and antibodies.</p>
<div class="lb-trans"><p>Rani Therapeutics Holdings, Inc. 作為一家臨牀階段的生物治療公司，開發用於美國患者、醫生和醫療系統的口服生物製劑。該公司開發了 RaniPill 膠囊，這是一種藥物無關的口服遞送平台，用於遞送多種藥物成分，包括寡核苷酸、肽、蛋白質和抗體。</p>
</div><h2>Further Reading</h2>
<div class="lb-trans"><h2>進一步閲讀</h2>
</div><ul>
<li>Five stocks we like better than Rani Therapeutics</li>
<li>Best ESG Stocks: 11 Best Stocks for ESG Investing</li>
<li>OpenAI's Restructuring Sets up What Could Be the Biggest IPO Ever</li>
<li>How to Short Nasdaq: An Easy-to-Follow Guide</li>
<li>2 Rare Earth Stocks the U.S. Government Doesn’t Want to Fail</li>
<li>Pets Are Big Business: 4 Big-Ticket Pet Stocks to Add to Your Portfolio</li>
<li>CrowdStrike Partners With CoreWeave But Investors Sell the News</li>
</ul>
<div class="lb-trans"><ul>
<li>我們更看好的五隻股票，而不是 Rani Therapeutics</li>
<li>最佳 ESG 股票：11 只最佳 ESG 投資股票</li>
<li>OpenAI 的重組為可能成為有史以來最大 IPO 的機會鋪平了道路</li>
<li>如何做空納斯達克：易於遵循的指南</li>
<li>美國政府不希望失敗的 2 只稀土股票</li>
<li>寵物是大生意：4 只大票寵物股票可加入您的投資組合</li>
<li>CrowdStrike 與 CoreWeave 合作，但投資者拋售消息</li>
</ul>
</div><p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/EarningsChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9UkFOSQ" alt="" original-src="https://www.marketbeat.com/scripts/EarningsChart.ashx?Prefix=NASDAQ&amp;Symbol=RANI"/></p>
<p><em>This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.</em></p>
<div class="lb-trans"><p><em>此即時新聞提醒由敍述科學技術和來自 MarketBeat 的金融數據生成，以便為讀者提供最快的報道和公正的覆蓋。請將任何問題或意見發送至 contact@marketbeat.com。</em></p>
</div><h2>Should You Invest $1,000 in Rani Therapeutics Right Now?</h2>
<div class="lb-trans"><h2>你現在應該投資 $1,000 在 Rani Therapeutics 嗎？</h2>
</div><p>Before you consider Rani Therapeutics, you'll want to hear this.</p>
<div class="lb-trans"><p>在考慮 Rani Therapeutics 之前，您需要聽聽這個。</p>
</div><p>MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Rani Therapeutics wasn't on the list.</p>
<div class="lb-trans"><p>MarketBeat 每天跟蹤華爾街頂級評級和表現最佳的研究分析師及其推薦的股票。MarketBeat 已識別出五隻頂級分析師正在悄悄向客户推薦的股票，以便在更廣泛的市場注意到之前購買... 而 Rani Therapeutics 並不在名單上。</p>
</div><p>While Rani Therapeutics currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.</p>
<div class="lb-trans"><p>雖然 Rani Therapeutics 目前在分析師中獲得了適度買入評級，但頂級分析師認為這五隻股票更值得購買。</p>
</div><p>View The Five Stocks Here</p>
<div class="lb-trans"><p>在這裏查看這五隻股票</p>
</div>

Rani Therapeutics (NASDAQ:RANI) 公佈季度財報，每股收益比預期低 0.03 美元